Clinical Trial Update: INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. [Phase 3]

View source ↗

Summary

Phase 3 trial update for INC424 in patients with myelofibrosis including primary, post-polycythemia myelofibrosis, or post-essential thrombocythemia myelofibros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• INC424 (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelofibrosis | Phase 3 | Status: COMPLETED | Results posted: 2019-04-26